news

CUPERTINO, Calif., Feb 17, 2010 /PRNewswire via COMTEX/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) fourth quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Wednesday, February 24, 2010 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: […]

BESST (Bupivacaine Effectiveness and Safety in SABER(TM) Trial) Targets Post-Surgical PainCUPERTINO, Calif., Jan 19, 2010 /PRNewswire via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today that it has begun dosing patients in its U.S. pivotal Phase III clinical trial to evaluate POSIDUR(TM) (SABER(TM)-Bupivacaine), an investigational drug, for the treatment of post-surgical pain. The pivotal trial,

CUPERTINO, Calif., Dec 17, 2009 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today positive results from a 60 patient Phase IIb clinical trial of POSIDUR(TM), a proprietary product under development for the treatment of post-surgical pain. Top line results from this study of patients undergoing arthroscopic shoulder surgery showed a consistent reduction of

CUPERTINO, Calif., Nov. 23 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, and Joe Stauffer, Chief Medical Officer, will be presenting at the 21st Annual Piper Jaffray Health Care Conference on Tuesday, December 1 at 3:30 pm Eastern Time. The conference is being held at the New York Palace

CUPERTINO, Calif., Oct 29, 2009 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) announced today financial results for the three months ended September 30, 2009. Total revenues were $8.4 million for the three months ended September 30, 2009, compared to $6.6 million for the same period in 2008; revenues in the 2009 period included $3.0

CUPERTINO, Calif., Oct. 26 /PRNewswire-FirstCall/ — In conjunction with DURECT Corporation’s (Nasdaq: DRRX) third quarter 2009 financial results press release, you are invited to listen to the conference call that will be broadcast live over the internet on Thursday, October 29, 2009 at 4:30 pm Eastern Time (1:30 pm Pacific Time). (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) A live

CUPERTINO, Calif., Sept. 17 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences. (Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO) — Matt Hogan, Chief Financial Officer, will present at the UBS Global Life Sciences Conference in New York on Wednesday, September 23rd at 10:30 a.m. Eastern Time. A live audio

CUPERTINO, Calif., Sept. 11 /PRNewswire-FirstCall/ — — DURECT Corporation (Nasdaq: DRRX) today reported that it has entered into a privately negotiated transaction to sell 4,444,444 primary shares of common stock to affiliates of Venrock at a price of $2.25 per share, raising net proceeds to DURECT of approximately $10 million. DURECT expects the financing to

CUPERTINO, Calif., Aug. 27 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) today reported that it has signed an exclusive long term excipient supply agreement with respect to REMOXY(R) with King Pharmaceuticals, Inc. (NYSE: KG). This agreement stipulates the terms and conditions under which DURECT will supply to King, based on DURECT’s manufacturing cost plus a specified

CUPERTINO, Calif., Aug 18, 2009 /PRNewswire-FirstCall via COMTEX/ — DURECT Corporation (Nasdaq: DRRX) today announced that it has signed a development and license agreement with Orient Pharma Co., Ltd., a diversified multinational pharmaceutical, healthcare and consumer products company with headquarters in Taiwan, under which DURECT has granted to Orient Pharma development and commercialization rights in